Morand P, Baudouy M, Camous J P, Gibelin P, Leborgne L
Ann Med Interne (Paris). 1985;136(3):266-71.
Dihydralazine, sold under the name of Nepressol, is the derivative of the hydrazinophthalazines used in France for the treatment of severe cardiac failure. The hydrazinophthalazines act in cardiac failure by decreasing systemic arterial resistance and increasing cardiac output without causing tachycardia or increasing myocardial contractility in normal or hypotensive subjects. The hydrazinophthalazines are metabolised by N-acetyl-transferase in the liver. The hepatic concentration of this enzyme is genetically determined. The immediate haemodynamic results observed with 100 to 300 mg/daily of Nepressol are impressive: an 86 p. 100 increase in cardiac output; a 75 p. 100 decrease in systemic valvular resistance; a 25 p. 100 fall in left ventricular filling pressures. These haemodynamic results are maintained at long-term (3 to 48 months). This treatment is associated with an improvement in symptoms and functional capacity. However, its efficacy in improving survival has not been demonstrated. Immunological complications giving rise to a lupic syndrome result only in biological changes and do not influence management.
双肼屈嗪，以Nepressol的名称销售，是肼酞嗪类的衍生物，在法国用于治疗严重心力衰竭。肼酞嗪类药物通过降低体循环动脉阻力和增加心输出量来治疗心力衰竭，在正常或低血压患者中不会引起心动过速或增加心肌收缩力。肼酞嗪类药物在肝脏中由N - 乙酰转移酶代谢。该酶的肝脏浓度由基因决定。每日服用100至300毫克Nepressol所观察到的即时血流动力学结果令人印象深刻：心输出量增加86%；体循环瓣膜阻力降低75%；左心室充盈压下降25%。这些血流动力学结果在长期（3至48个月）内得以维持。这种治疗与症状和功能能力的改善相关。然而，其在提高生存率方面的疗效尚未得到证实。导致狼疮综合征的免疫并发症仅引起生物学变化，并不影响治疗管理。
